These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 23447395)
1. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows. Cohen D BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395 [No Abstract] [Full Text] [Related]
2. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge]. Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535 [No Abstract] [Full Text] [Related]
3. Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise. Prescrire Int; 2011 Nov; 20(121):267. PubMed ID: 22066314 [No Abstract] [Full Text] [Related]
4. A cohort study of acute pancreatitis in relation to exenatide use. Dore DD; Bloomgren GL; Wenten M; Hoffman C; Clifford CR; Quinn SG; Braun DK; Noel RA; Seeger JD Diabetes Obes Metab; 2011 Jun; 13(6):559-66. PubMed ID: 21320263 [TBL] [Abstract][Full Text] [Related]
5. [New class of oral antidiabetic drugs. Effective in combination with metformin]. MMW Fortschr Med; 2007 Jan; 149(1-2):17. PubMed ID: 17619359 [No Abstract] [Full Text] [Related]
6. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4? Xu L; Spinas GA; Niessen M Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848 [No Abstract] [Full Text] [Related]
7. GLP-1-based therapies: the dilemma of uncertainty. Spranger J; Gundert-Remy U; Stammschulte T Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985 [No Abstract] [Full Text] [Related]
8. Journal withdraws article after complaints from drug manufacturers. Hawkes N BMJ; 2011 Apr; 342():d2335. PubMed ID: 21482597 [No Abstract] [Full Text] [Related]
9. Pancreatitis associated with incretin-based therapies. Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376 [No Abstract] [Full Text] [Related]
10. Exenatide and rare adverse events. Ahmad SR; Swann J N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920 [No Abstract] [Full Text] [Related]
12. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333 [TBL] [Abstract][Full Text] [Related]
13. [Treatment with new preparations against type 2 diabetes not sufficiently documented]. Karlsson EA; Palmér M; Malmström R Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713 [No Abstract] [Full Text] [Related]
15. Using prandial insulin to achieve glycemic control in type 2 diabetes. Dailey GE J Fam Pract; 2007 Sep; 56(9):735-42. PubMed ID: 17764645 [No Abstract] [Full Text] [Related]
16. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Pendergrass M; Fenton C; Haffner SM; Chen W Diabetes Obes Metab; 2012 Jul; 14(7):596-600. PubMed ID: 22268550 [TBL] [Abstract][Full Text] [Related]
17. Sitagliptin/metformin (Janumet) for type 2 diabetes. Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377 [No Abstract] [Full Text] [Related]
18. Sitagliptin: too many cases of pancreatitis. Prescrire Int; 2010 Apr; 19(106):75. PubMed ID: 20568683 [No Abstract] [Full Text] [Related]
19. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616 [TBL] [Abstract][Full Text] [Related]
20. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2]. Musch A; Heinzl S Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807 [No Abstract] [Full Text] [Related] [Next] [New Search]